<DOC>
	<DOCNO>NCT00894569</DOCNO>
	<brief_summary>The purpose study determine whether addition cetuximab carboplatin/paclitaxel improve efficacy comparison carboplatin/paclitaxel patient carcinoma unknown-primary .</brief_summary>
	<brief_title>Paclitaxel/Carboplatin With Without Cetuximab CUP</brief_title>
	<detailed_description>Carcinomas unknown primary ( CUP ) account approximately 2-5 % cancer diagnose . Except subset favorable prognosis , patient , treatment option limit , standard first-line regimen identify . Standard therapy patient adeno- undifferentiated CUP Paclitaxel/Carboplatin , yield response rate 20-40 % . In recent year , target therapy inhibitor EGFR , several tyrosine kinase , VEGF show improve survival different solid tumor entity . Cetuximab , monoclonal antibody EGF receptor , prove efficacy combination chemotherapy patient metastatic colorectal cancer , gastric cancer , squamous cell carcinoma head neck non-small cell lung cancer ( NSCLC ) . Because promising result seem reasonable examine impact add cetuximab standard chemotherapy paclitaxel carboplatin patient CUP .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologic cytologic proven , nonresectable carcinoma unknown primary ( adenocarcinoma nondifferentiated carcinoma ) Measurable tumor lesion ( ) accord RECIST criterion WHO PS 0 1 Paclitaxel/Carboplatin without Cetuximab Adeno Undifferentiated CUP ( PACETCUP ) Signed write informed consent ≥ 18 year age Effective contraception male female subject risk conception exists Adequate bone marrow function : Neutrophiles blood cell count ( NBC ) ≥ 1,5x109/L Platelet count ≥ 100x109/L Hemoglobin ≥ 5,00 mmol/L ( 8 g/dL ) Adequate liver renal function : Bilirubin ≤ 1,5 x upper normal level ( UNL ) increase 25 % within last 4 week ASAT ALAT ≤ 2,5 x UNL case liver metastases ≤ 5 x UNL Serum creatinine ≤ 1.5 x UNL Previous exposure epidermal growth factor receptortargeting therapy Previous chemotherapy except adjuvant treatment progression disease document &gt; 6 month end adjuvant treatment Radiotherapy major abdominal thoracic surgery within last 4 week inclusion Concurrent chronic systemic immunotherapy , chemotherapy hormone therapy Investigational agent participation clinical trial within 30 day treatment start study Clinically relevant coronary disease myocardial infarction within 12 month study entry Possibility curative local treatment ( surgery and/or radiotherapy ) Women axillary node metastasis predominant tumor site Women peritoneal carcinomatosis predominant tumor site Men &lt; 50 year old retroperitoneal mediastinal lymph node +/ lung metastasis predominant tumor site Identification primary suspicion specific tumor entity reference histopathology ( i.e. , Her2 positive hormone receptor positive tumor correspond breast cancer , CK7negative/CK20 positive tumor high probability colorectal cancer ) Peripheral neuropathy &gt; CTC grade I Previous malignancy within last 5 year ( except history basal cell carcinoma skin preinvasive carcinoma cervix adequate treatment ) History severe psychiatric illness Life expectancy less six week Drug alcohol abuse Known hypersensitivity reaction component study treatment Pregnancy ( absence confirm βhCG test ) lactation period Brain metastasis and/or leptomeningeal disease ( know suspect ) Acute subacute intestinal occlusion inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>carcinoma unknown primary</keyword>
	<keyword>cancer unknown primary</keyword>
	<keyword>CUP</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>cetuximab</keyword>
</DOC>